

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



September 25, 2025

To whom it may concern:

Company name	KISSEI PHARMACEUTICAL CO., LTD.
Representative	Mutsuo Kanzawa, Chairman and CEO (Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact	Takahide Kitahara, Managing Director, Department Manager of Corporate Finance and Management Department, CFO (Telephone +81-263-25-9081)

Notice Regarding Sale of Investment Securities (Result)

KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that the sale of investment securities, which was disclosed on July 29, 2025, has been completed as detailed below.

(1) Result of the sale of investment securities

- | | |
|--|---|
| (i) Shares sold: | Two listed stocks held by the Company |
| (ii) Period of sale: | From August 4, 2025 to September 25, 2025 |
| (iii) Gain on sale of investment securities: | ¥11,605 million |

(2) Future Outlook

The gain on sales of investment securities mentioned above has already been incorporated into the consolidated earnings forecast for the second quarter (interim period) and the full fiscal year ending March 31, 2026, which was announced on July 29, 2025. Therefore, there will be no revision to the earnings forecast due to this transaction.

(Reference)

Content Announced on July 29, 2025.

Recording of Extraordinary Income

(1) Reason for the Sale of Investment Securities.

The purpose is to improve medium- to long-term return on capital by allocating cash obtained from the sale of investment securities to growth investments, primarily in R&D. The Company is working to improve capital efficiency toward the realization of management that is conscious of the cost of capital and stock price, and this matter is part of such efforts.

(2) Overview of the Sale of Investment Securities

- | | |
|---|--|
| (i) Shares sold (plan): | Two listed stocks held by the Company |
| (ii) Period of sale (plan): | From July 30, 2025 to September 30, 2025 |
| (iii) Gain on sale of investment securities (forecast): | Approx. ¥12,000 million |

-End-